期刊
BRITISH JOURNAL OF CANCER
卷 97, 期 2, 页码 145-151出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603860
关键词
gemcitabine; pharmacogenomics; polymorphisms; gene expression; tailor-made therapy
类别
Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据